Mycobacterial PIMs inhibit host inflammatory responses through CD14-dependent and CD14-independent mechanisms

Area of Science:

• Immunology
• Microbiology
• Molecular Biology

Background:

• Mycobacteria employ immune evasion strategies, including the use of phenolic glycolipids (PIMs) to suppress host inflammatory responses.
• PIMs, such as lipoarabinomannan (LAM) and PIMs, are known to inhibit pro-inflammatory cytokine production by macrophages.

Purpose of the Study:

• To investigate the precise mechanism by which synthetic PIM analogues exert their anti-inflammatory effects.
• To elucidate the role of CD14 in the PIM-mediated inhibition of Toll-like receptor (TLR) signaling.

Main Methods:

• Utilized synthetic PIM(1) isomer and PIM(2) mimetic analogues.
• Assessed inhibition of TNF and IL-12 p40 expression in murine macrophages stimulated via TLR2, TLR4, or TLR9 pathways.
• Investigated the binding of lipopolysaccharide (LPS) to TLR4/MD2/CD14 complex using HEK cells.
• Employed CD14-deficient macrophages and rough-LPS to differentiate between CD14-dependent and independent effects.

Main Results:

• Synthetic PIM(1) and PIM(2) analogues potently inhibited TNF and IL-12 p40 expression induced by TLR2 and TLR4 pathways, but not TLR9.
• PIM analogues were shown to inhibit LPS binding to the TLR4/MD2/CD14 complex, specifically at the CD14 level.
• While TNF inhibition by PIMs was CD14-dependent, IL-12 p40 inhibition was CD14-independent, indicating multifaceted inhibitory actions on the TLR4 pathway.

Conclusions:

• Synthetic PIM analogues effectively suppress TLR2 and TLR4-mediated inflammatory responses.
• PIMs exhibit distinct mechanisms for inhibiting different cytokines, with CD14 playing a role in TNF suppression but not IL-12 p40 suppression.
• These findings highlight the complex immunomodulatory roles of PIMs in mycobacterial infections and suggest potential therapeutic applications.